Antoine Francis: The Hidden Power of Albumin
Antoine Francis, Founder of Global Plasma Supply LTD, has shared on LinkedIn:
”I have spent my career studying plasma—and the deeper I examine albumin, the more extraordinary this molecule becomes.
It is so abundant that medicine can mistake familiarity for simplicity.
But albumin is not simple.
- It helps determine where fluid remains within the body. It transports substances that cannot circulate safely alone. It carries fatty acids, hormones, bilirubin, metals and medicines.
- It absorbs oxidative injury, supports vascular integrity and continuously moves between the bloodstream, tissues and lymphatic system.
- It is measured as a concentration.
But it behaves as an entire physiological system.
Today, Global Plasma Supply is releasing Parts I and II of:
- Albumin: The Master Molecule
- The Silent Guardian of Human Physiology
- This volume begins with the molecule itself and then follows its silent work throughout the circulation.
My objective was not to produce another dry scientific summary.
I wanted clinicians, scientists, industry leaders, and curious readers to see what I see when I look at albumin:
- Not merely a laboratory result.
- Not merely a colloid.
- Not merely another fractionated protein.
But one of the most abundant, versatile and strategically important molecules in human medicine.
And behind every future clinical vial stands something equally important:
- A donor.
- A collection system.
- A fractionation process.
- A global supply chain.
And a patient whose life may depend upon all of them working together.
This is only the beginning of Volume II. The next parts will move from physiology to bedside medicine, donor-derived manufacturing, global albumin markets, supply security and the emerging technologies that may shape its future.
Albumin is not merely carried within plasma. It is one of the principal reasons plasma can sustain life.
Always think donation
Always think life.”

More posts featuring Antoine Francis on Hemostasis Today.
-
Aug 17, 2026, 17:03Ahmad Hazri Mohamed Aris: Strengthening Hemophilia Care in Fiji
-
Aug 17, 2026, 16:56Suspicion-Based Screening for Occult Malignancy in Lower Extremity Venous Thrombosis – JTH
-
Aug 17, 2026, 16:51Kathaleen Schnur: Celebrating The Bleeding Disorders Community
-
Aug 17, 2026, 16:45Eugenio Caradonna: Can Light Replace Chemicals in PRP Activation?
-
Aug 17, 2026, 16:30Jeff Sternlicht: We Don’t Measure Lp(a) Because We Have a Drug
-
Aug 17, 2026, 16:22Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
-
Aug 17, 2026, 15:13Gabriela A.: New FDA Approval Advances the Future of Dried Plasma
-
Aug 17, 2026, 15:01Alan Dursun: When Haemophilia Care Becomes a Reality
-
Aug 17, 2026, 14:58Registrations are Still Open for the EHC Health Economics Course 2026